An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI)

Murillo, Espitia L; Sutachan, J.J; Albarracín, S L

doi:10.1016/j.toxrep.2023.04.015

Cited by 9 publications

(2 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principal mechanisms behind CRCI involve oxidative stress and inflammation, 3 which lead to cognitive decline by causing disruptions in the blood–brain barrier, neuroinflammation, neurotransmitter dysfunction, and decreased neurogenesis. 4 , 5 Cognitive impairment can result from chemotherapy, other cancer treatments, the cancer itself, and noncancer-related factors. For instance, hormonal therapy for breast cancer can suppress estrogen secretion, affecting cognitive function.…”

Section: Mechanismsmentioning

confidence: 99%

Chemotherapy-related cognitive impairment: What we need to know and what we can do

Miyashita

2024

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Section: Mechanismsmentioning

confidence: 99%

Chemotherapy-related cognitive impairment: What we need to know and what we can do

Miyashita

2024

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

“…[ 3 ] At the cellular level chemotherapy may lead to neural loss and synaptic dysfunction, induce neuroinflammatory responses, and disrupt brain energy metabolism. [ 8 ] These neuropathological alterations can be measured noninvasively using proton magnetic resonance spectroscopy (MRS).…”

Section: Introductionmentioning

confidence: 99%

Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study

Beyer,

Couch,

Ruddy

et al. 2023

Medicine

View full text Add to dashboard Cite

Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We analyzed 11 women with newly diagnosed stage 1 to 3 breast cancer. Patients were evaluated via objective cognitive testing, and patient self-report tests. Patients were examined using single voxel proton magnetic resonance spectroscopy in the medial frontal cortex, posterior cingulate gyrus, and left thalamus at baseline and after the completion of chemotherapy on a 1.5 Tesla scanner. At the posttreatment evaluation as compared to baseline, 7 of the 10 (70%) patients reported worsening memory on the MD Anderson symptom inventory (annualized change = 1.82 ± 2.88, P = .08), while the delayed recall raw score of the Rey Osterrieth complex figure test did not change from pre- to post-chemotherapy (mean annualized change = 5.00 ± 14.38, P = .30). The annualized change in the creatine concentration in the posterior cingulate gyrus was statistically significant. The annualized change in the MD Anderson symptom inventory was negatively correlated with the annualized change in the medial frontal N-acetylaspartate (Spearman correlation coefficient [rho] = −0.78, P = .01) and positively correlated with the annualized change in the posterior cingulate gyrus creatine (rho = 0.66, P = .04). Annualized changes in the Rey Osterrieth complex figure test were positively correlated with annualized changes in choline (rho = 0.83, P = .01) in the medial frontal cortex, choline (rho = 0.76, P = .04) in the left thalamus, and creatine (rho = 0.73, P = .02) in the medial frontal cortex. Our data suggest that chemotherapy may lead to the worsening of self-reported memory function, which is associated with alterations in brain metabolites.

show abstract

Dementia and chemotherapy

Meran

2024

Onkologie

View full text Add to dashboard Cite

An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI)

Cited by 9 publications

References 91 publications

Chemotherapy-related cognitive impairment: What we need to know and what we can do

Chemotherapy-related cognitive impairment: What we need to know and what we can do

Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study

Dementia and chemotherapy

Contact Info

Product

Resources

About